-
1
PST-611 trial completed phase 1 with last patient visit.
-
2
Evaluated safety and tolerability in six patients.
-
3
Conducted in Paris and Grenoble.
-
4
Results to be presented at ARVO Annual Meeting
-
5
Aims to address dysregulated iron homeostasis in dry AMD.
-
6
Uses electro-transfection for DNA delivery.
-
7
Potential for less invasive treatment options.
-
8
Focus on preserving visual function.
Original Source(s)
Related Content
Ocugen GA Trial Advances Toward Phase 3
Ocugen reports positive Phase 2 data for its OCU410 gene therapy in geographic atrophy
May 1, 2026
-
3 min
TULIP: A New Approach to IOP Reduction
Low-power ultrasound biomodulation may offer a noninvasive, repeatable strategy to lower IOP without tissue destruction.
May 1, 2026
-
10 min
Emerging Technologies in Continuous IOP Monitoring
Wearable and implantable devices offer new data on pressure variability, though barriers to routine use persist.
by Khushi Saigal, BA, Rachel Chapman, Samantha Goldburg, MD, Mary Qiu, MD,
May 1, 2026
-
22 min
